Multicenter open-label, phase IIB study with 0.5 mg / day Entecavir (BARACLUDE ) in patients with positive HBsAg solid or hematologic malignancies undergoing chemotherapy (ChemET) (ChemET).

Trial Profile

Multicenter open-label, phase IIB study with 0.5 mg / day Entecavir (BARACLUDE ) in patients with positive HBsAg solid or hematologic malignancies undergoing chemotherapy (ChemET) (ChemET).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2012

At a glance

  • Drugs Entecavir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms ChemET
  • Most Recent Events

    • 06 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top